Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 6/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 3/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.65 |
| ▸ | CRHBP | P24387 | 1/20 | 0.64 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16233245 | 0.88 | SLC6A5 (0.79) | SLC6A5THRBTP53OPRM1OPRD1 | |
| SCHEMBL16233174 | 0.88 | SLC6A5 (0.79) | SLC6A5THRBTP53OPRM1OPRD1 | |
| SCHEMBL5015969 | 0.81 | SLC6A5 (1.00) | SLC6A5THRBTP53OPRM1OPRD1 | |
| SCHEMBL16233241 | 0.80 | TP53 (1.00) | SLC6A5THRBTP53OPRM1CRHBP | |
| SCHEMBL5015981 | 0.79 | SLC6A5 (1.00) | SLC6A5THRBTP53CRHBPCRHR2 | |
| SCHEMBL5015977 | 0.79 | OPRM1 (0.74) | SLC6A5THRBTP53OPRM1OPRD1 | |
| SCHEMBL8285579 | 0.78 | SLC6A5 (0.64) | SLC6A5TP53ALDH1A1LMNA | |
| SCHEMBL5024761 | 0.77 | OPRM1 (0.72) | SLC6A5THRBTP53OPRM1OPRD1 | |
| SCHEMBL13754058 | 0.75 | MMP1 (0.70) | SLC6A5ALDH1A1LMNA | |
| SCHEMBL5017447 | 0.74 | OPRM1 (0.68) | SLC6A5THRBTP53OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1419138-B1 | N- (1-DIMETHYLAMINOCYCLOALKYL)METHYL BENZAMIDE DERIVATIVES | ORGANON NV (NL) | 2008-10-29 | — | — | EP | disclosed |
| US-7126027-B2 | N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives | AKZO NOBEL N.V. (NL) | 2006-10-24 | — | — | US | disclosed |
| US-20040242685-A1 | N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives | N.V. ORGANON (NL) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242685-A1 | N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives | SLC1A2, SLC6A1, KCNT2 | SLC6A5 26/4885THRB 2336/4885TP53 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.